RTP Mobile Logo
Hematologic Oncology Update, Issue 3, 2016 (Video Program)
Released March 2017

Highlights from video interviews with Drs Sagar Lonial, Loretta J Nastoupil, Laurie H Sehn and Raoul Tibes on the treatment of hematologic cancers.

CE Disclosures and Faculty Information

    This activity is intended for medical oncologists, hematologists, hematology-oncology fellows and other healthcare providers involved in the treatment of hematologic cancers.

    The treatment of hematologic cancer remains a challenge for many healthcare professionals despite recent gains made in the management of this group of diseases. Determining which treatment approach is most appropriate for a given patient requires careful consideration of patient-specific characteristics, physician expertise and available health system resources. To bridge the gap between research and patient care, this issue of Hematologic Oncology Update features one-on-one discussions with leading hematology-oncology investigators. By providing information on the latest clinical developments in the context of expert perspectives, this activity assists medical oncologists, hematologists and hematology-oncology fellows with the formulation of evidence-based and current therapeutic strategies, which in turn facilitates optimal patient care.


    • Consider current and emerging clinical research data in the formulation of therapeutic recommendations for patients with newly diagnosed and relapsed/refractory follicular, mantle cell and diffuse large B-cell lymphomas. 
    • Appreciate the recent FDA approvals of several novel therapies for the treatment of newly diagnosed and relapsed/refractory chronic lymphocytic leukemia, and discern how these therapies can be appropriately and safely integrated into routine clinical practice. 
    • Reevaluate current treatment approaches for patients with myeloproliferative disorders and acute and chronic leukemias in light of newly emerging clinical trial data.
    • Assess the benefits and risks of evidence-based systemic treatment options to optimize the care of patients with peripheral T-cell lymphoma.
    • Consider available research data and other clinical factors in the best-practice selection, sequencing and combining of current and recently approved novel agents in the nonresearch care of patients with relapsed/refractory multiple myeloma.

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CME credit is no longer available for this issue


    CME credit is no longer available for this issue


    CME credit is no longer available for this issue

    This CME activity consists of a video component.

    CME credit is no longer available for this issue

    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Sagar Lonial, MD
    Professor and Executive Vice Chair
    Department of Hematology and Medical Oncology
    Chief Medical Officer
    Winship Cancer Institute
    Emory University
    Atlanta, Georgia 

    Advisory Committee and Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals, an Amgen subsidiary, Takeda Oncology. 

    Loretta J Nastoupil, MD
    Assistant Professor, Department of Lymphoma/Myeloma
    Division of Cancer Medicine
    Director, Lymphoma Outcomes Database
    The University of Texas MD Anderson Cancer Center
    Houston, Texas 

    Advisory Committee: Gilead Sciences Inc, Janssen Biotech Inc, TG Therapeutics Inc; Consulting Agreement: Gilead Sciences Inc; Contracted Research: Abbott Laboratories, Celgene Corporation, Genentech BioOncology, Janssen Biotech Inc, TG Therapeutics Inc. 

    Laurie H Sehn, MD, MPH
    Centre for Lymphoid Cancer
    BC Cancer Agency and University of British Columbia
    Vancouver, British Columbia, Canada 

    Consulting Agreements: AbbVie Inc, Amgen Inc, Celgene Corporation, Genentech BioOncology, Janssen Biotech Inc, Lundbeck, Roche Laboratories Inc, Seattle Genetics, Takeda Oncology, TG Therapeutics Inc. 

    Raoul Tibes, MD, PhD
    Consultant, Mayo Clinic
    Assistant Professor of Medicine, Mayo College of Medicine
    Scholar in Clinical Research, Leukemia and Lymphoma Society
    Scottsdale, Arizona 

    Clinical Trial Funding: Astellas Pharma Global Development Inc, Merck, Novartis Pharmaceuticals Corporation. 

    EDITOR — Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma, Agendia Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Baxalta Inc, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, CTI BioPharma Corp, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lexicon Pharmaceuticals Inc, Lilly, Medivation Inc, a Pfizer Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, NanoString Technologies, Natera Inc, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro Inc, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Amgen Inc, Astellas Pharma Global Development Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, Incyte Corporation, Janssen Biotech Inc, Novartis Pharmaceuticals Corporation, Pharmacyclics LLC, an AbbVie Company, Seattle Genetics and Takeda Oncology.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: March 2017
    Expiration date: March 2018

Acknowledge and close

Watch video
(WIFI is recommended for best performance):

Non-Hodgkin lymphoma (NHL), Hodgkin lymphoma and chronic lymphocytic leukemia (CLL)

  • Obinutuzumab: Mechanism of action, activity and management of treatment-associated infusion reactions
  • Results of the Phase III GADOLIN and GALLIUM studies evaluating obinutuzumab-based therapy for NHL
  • Activity of FDA-approved (idelalisib) and investigational (copanlisib) PI3K inhibitors in indolent NHL
  • RELEVANCE: A Phase III trial evaluating lenalidomide/rituximab (R2) versus rituximab-based chemotherapy followed by maintenance rituximab for previously untreated follicular lymphoma
  • Case discussion: A 62-year-old man with chemotherapy-refractory diffuse large B-cell lymphoma whose disease is controlled with R2 achieves a complete response with chimeric antigen receptor T-cell (CAR-T) therapy
  • Clinical approach to CAR-T therapy and management of associated cytokine release syndrome
  • Efficacy and toxicity profile of CAR-T therapy in lymphomas
  • Administration of most closely HLA-matched multivirus-specific (“off the shelf”) T-cell therapy
  • Sequencing of therapeutic options for relapsed mantle cell lymphoma
  • Case discussion: A 72-year-old woman with relapsed/refractory peripheral T-cell lymphoma receives romidepsin
  • Results of the Phase III AETHERA trial: Progression-free survival improvement with brentuximab vedotin as consolidation therapy after autologous stem cell transplant in patients with HL at risk of relapse or progression
  • First-line therapy for CLL
  • Integration of venetoclax into the treatment algorithm for CLL
  • Activity and tolerability of the Bruton tyrosine kinase inhibitors ibrutinib and acalabrutinib (ACP-196) in CLL

Acute and chronic leukemias and myeloproliferative neoplasms

  • Case discussion: A 54-year-old woman with relapsed/refractory acute myeloid leukemia (AML)
  • Approach to FLT3 and other mutation testing for patients with AML
  • Comparison of the FLT3 inhibitors midostaurin, quizartinib, gilteritinib and sorafenib in AML
  • Activity of the Bcl-2 inhibitor venetoclax in patients with AML
  • Case discussion: A 36-year-old woman with relapsed/refractory acute lymphoblastic leukemia achieves complete remission with blinatumomab
  • Case discussion: A 36-year-old man is newly diagnosed with chronic-phase chronic myeloid leukemia
  • Activity of ruxolitinib in myeloproliferative neoplasms and therapeutic options for patients who experience a response followed by disease progression

Multiple myeloma (MM)

  • Management of high-risk MM
  • Emergence of ixazomib as a component of maintenance therapy for high-risk MM
  • Early versus delayed autologous transplant after induction therapy for MM
  • Biologic rationale for combining daratumumab with immunomodulatory drugs or immune checkpoint inhibitors
  • Case discussion: A 75-year-old woman with indolent MM and disease progression on maintenance lenalidomide receives ixazomib/lenalidomide/dexamethasone
  • Strategies for promoting Bcl-2 dependence to increase venetoclax sensitivity in patients with MM
  • Emerging research with CAR-T therapy in MM